Astellas Pharma Inc (OTCPK:ALPMY)
$ 9.49 -0.19 (-1.96%) Market Cap: 17.02 Bil Enterprise Value: 20.86 Bil PE Ratio: 0 PB Ratio: 1.78 GF Score: 77/100

Q3 2020 Astellas Pharma Inc Earnings Call Transcript

Jan 31, 2020 / 05:30AM GMT
Release Date Price: $17.62 (+0.20%)
Naoki Okamura
Astellas Pharma Inc. - Chief Strategy Officer, CFO, Corporate Executive VP & Representative Director

I'm the CSO and CFO, Naoki Okamura. Thank you very much for participating in the conference call by Astellas on the third quarter financial results for fiscal year 2019. Today, the time is limited. So initially, I'd like to spend about 20 minutes to give you an overview of the financial results and explain the initiatives for sustainable growth and capital allocation. And then we will entertain your questions later.

Page 2 is a cautionary statement regarding forward-looking information, which was already read, so please turn to Page 4. First of all, this is an overview of the third quarter financial results based on year-on-year comparisons. Revenue and core operating profit declined, but excluding ForEx impact, revenue and profit increased. So our business progressed favorably as expected, due to the LOE of Tarceva, VESIcare in the United States and Europe and Tarceva in the United States and termination of Symbicort and KM bioproducts in Japan, sales declined substantially.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot